Aducanumab: Biogen Is The Latest Firm To Preempt A Negative EU Opinion On Approval

 
• By Ian Schofield

The EU marketing application for aducanumab is heading for a rejection for Alzheimer’s disease, according to a “negative trend vote” at the CHMP disclosed by the drug’s sponsors.

Pills with euro union flag, medicine
The CHMP can OK or reject EU drug approval applications • Source: Shutterstock

More from Europe

More from Geography